Cancer Treatment Landscape: Modalities, Precision Oncology, and the Quest for Cures

Why No Single "Cure" Exists

Cancer comprises >200 molecularly distinct diseases. Each has unique driver mutations, microenvironment, and evolutionary trajectory. "Cure" requires eradicating every clonogenic cell—a bar not yet met for most metastatic solid tumors.

Current Modalities

Modality	Mechanism	Curative Settings
Surgery	Local excision ± lymphadenectomy	Early-stage solid tumors (breast, colon, melanoma, etc.)
Radiation	DNA damage → mitotic catastrophe	Localized (H&N, cervix, prostate, lymphoma)
Chemotherapy	Cytotoxic (cell-cycle or DNA-targeted)	Germ cell, lymphoma, leukemia, adjuvant/neoadjuvant
Targeted Therapy	Oncogene addiction (EGFR, ALK, BRAF, BCR-ABL)	CML (TKI → functional cure), subsets of NSCLC, melanoma
Immunotherapy	Checkpoint blockade (PD-1/PD-L1, CTLA-4), CAR-T, BiTEs	Melanoma, NSCLC, RCC, Hodgkin, B-ALL (CAR-T)
Hormone Therapy	ER/AR deprivation	Breast, prostate (adjuvant/metastatic control)
Cellular Therapy	CAR-T, TIL, NK cells	Relapsed/refractory B-cell malignancies

Precision Oncology Workflow

1. Comprehensive genomic profiling (tissue/liquid biopsy).
2. Molecular tumor board matches alterations to trials/approved drugs.
3. Biomarker-driven treatment (e.g., NTRK inhibitors, KRAS G12C, RET, METex14).

Frontiers

• Multi-omics + AI for neoantigen prediction.
• Early detection: multi-cancer early detection (MCED) blood tests.
• Prevention: vaccines (HPV, HBV), chemoprevention (tamoxifen, aspirin).

Realistic Framing

Many cancers become chronic, controllable conditions. "Functional cure" (long-term remission off therapy) is an emerging endpoint. Research continues toward true eradication.